Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibito...
November 21 2017 - 8:00AM
Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led,
biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today
announced that Dr. Gabriel Mbalaviele presented data from
pre-clinical studies of Aclaris’ recently acquired drug candidate,
ATI-450 (formerly known as CDD-450), a selective inhibitor of the
p38/MK2 pathway, at a symposium at the American College of
Rheumatology annual meeting earlier this month. The abstract
summarizing the data is titled “NOMID-Associated Complications in
Mice Are Prevented By CDD-450, a Small Molecule Inhibitor of the
Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2)
Pathway.”
In pre-clinical studies, ATI-450 was active in blocking multiple
manifestations of the Neonatal-onset Multisystem Inflammatory
Disease (NOMID) form of Cryopyrin associated periodic syndromes
(CAPS) using an inducible transgenic murine model of the disease.
CAPS are a spectrum of diseases arising from the gain of function
mutations in NLRP3, a key component of the inflammasome, resulting
in elevated systemic IL-β levels. Furthermore, ATI-450 inhibited
cold-induced production of IL-1β from the blood of patients with
another CAPS syndrome, Familial Cold Autoinflammatory Syndrome
(FCAS). These results confirm the key role of the p38/MK2 pathway
in the IL-1β biosynthetic pathway and suggest the potential for
ATI-450 to be an oral treatment for CAPS.
“This data is compelling, and clearly, further evaluation of
ATI-450 as a potential oral treatment for CAPS is warranted,” said
Dr. Joseph Monahan, Executive Vice President, Research &
Development of Aclaris. “We look forward to advancing this program
towards the clinic.”
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology.
Aclaris is focused on large, underserved market segments with no
FDA-approved medications or where treatment gaps exist.
Aclaris is based in Malvern, Pennsylvania and more information can
be found by visiting the Aclaris website at www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
"believe", "expect", "may", "plan," "potential," "will," and
similar expressions, and are based on Aclaris' current beliefs and
expectations. These forward-looking statements include expectations
regarding Aclaris’ preclinical and clinical development of its
product candidates. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Risks and uncertainties
that may cause actual results to differ materially include
uncertainties inherent in the conduct of clinical trials, Aclaris'
reliance on third parties over which it may not always have full
control, and other risks and uncertainties that are described in
the Risk Factors section of Aclaris' Annual Report on Form 10-K for
the year ended December 31, 2016, Aclaris’ Quarterly Report on Form
10-Q for the quarter ended September 30, 2017, and other filings
Aclaris makes with the U.S. Securities and Exchange Commission from
time to time. These documents are available under the "Financial
Information" section of the Investors page of Aclaris' website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact: Aclaris Contact Michael Tung, M.D.
Investor Relations 484-329-2140 mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024